Bayer (FRA:BAYN) has been assigned a €125.00 ($154.32) price objective by stock analysts at UBS Group in a report released on Monday, www.boersen-zeitung.de reports. The brokerage presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price objective would indicate a potential upside of 27.79% from the company’s previous close.
Several other research analysts have also recently issued reports on the stock. Baader Bank set a €140.00 ($172.84) target price on shares of Bayer and gave the company a “buy” rating in a report on Tuesday, February 6th. Sanford C. Bernstein set a €129.00 ($159.26) target price on shares of Bayer and gave the company a “buy” rating in a report on Friday, February 2nd. JPMorgan Chase & Co. set a €128.00 ($158.02) target price on shares of Bayer and gave the company a “buy” rating in a report on Tuesday, January 30th. DZ Bank restated a “buy” rating on shares of Bayer in a report on Wednesday, January 24th. Finally, Goldman Sachs Group set a €125.00 ($154.32) target price on shares of Bayer and gave the company a “buy” rating in a report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of €121.71 ($150.26).
Bayer (BAYN) opened at €97.82 ($120.77) on Monday. Bayer has a twelve month low of €93.30 ($115.19) and a twelve month high of €123.82 ($152.86). The stock has a market cap of $81,670.00 and a price-to-earnings ratio of 23.13.
WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/bayer-bayn-given-a-125-00-price-target-at-ubs-group.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.